Toby Maher, MD, PhD, professor of clinical medicine, Keck Medicine of USC, discusses recent advancements in clinical trials for patients with idiopathic pulmonary fibrosis (IPF) and progressive ...
Panelists discuss how progressive pulmonary fibrosis (PPF) and idiopathic pulmonary fibrosis (IPF), though distinct in etiology, share a common trajectory of irreversible lung scarring and functional ...
JASCAYD® (nerandomilast) now approved by Japan's MHLW for the treatment of adults with idiopathic pulmonary fibrosis and adults with progressive pulmonary fibrosis Approval enables access to the first ...
ICF001 为肺部靶向前药制剂，长效吸入前药设计逻辑优势显著，此次新增两项新适应症临床研究将极大提升临床价值。该四项适应症预期将基于共同的分子、制剂、给药装置及临床药理平台进行开发，此举有助提升研发效率。
2026 年 8 月24日，港股吸入给药赛道龙头长风药业长风药业（02652.HK）传来传来关键获批节点，自研长效吸入粉雾剂 ICF001 继 3 月拿下 PAH、PH‑ILD 临床试验默示许可后，再获 IPF、PPF ...
ICF001为肺部靶向前药制剂，长效吸入前药设计逻辑优势显著，此次新增两项新适应症临床研究将极大提升临床价值。于中国，PAH的治疗已趋向多机制联合用药，但吸入制剂及长效前药产品的供应仍然有限，而PH-ILD、IPF及PPF领域仍存在未被满足的临床需求 ...
A new pooled analysis of the FIBRONEERTM-IPF and FIBRONEERTM-ILD trials resulted in a nominally significant reduction in the risk of death by 59% in patients who received 18mg nerandomilast without ...
Boehringer Ingelheim has received Japan’s Ministry of Health, Labour and Welfare (MHLW) approval for Jascayd (nerandomilast) to treat adults with idiopathic pulmonary fibrosis (IPF) and progressive ...
The MarketWatch News Department was not involved in the creation of this content. -- A new pooled analysis of the FIBRONEER(TM)-IPF and FIBRONEER(TM)-ILD trials resulted in a nominally significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results